NP001 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	3

2. 筋萎縮性側索硬化症

---

臨床試験数 : 624 /  薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02794857 (ClinicalTrials.gov)	August 29, 2016	24/5/2016	Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation	Amyotrophic Lateral Sclerosis	Drug: NP001;Drug: Placebo	Neuraltus Pharmaceuticals, Inc.	NULL	Completed	21 Years	80 Years	All	138	Phase 2	United States;Canada
2	NCT01281631 (ClinicalTrials.gov)	February 2011	17/1/2011	A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: NP001;Drug: Placebo	Neuraltus Pharmaceuticals, Inc.	NULL	Completed	21 Years	80 Years	Both	136	Phase 2	United States
3	NCT01091142 (ClinicalTrials.gov)	July 2010	19/3/2010	Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)	Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: NP001;Drug: Placebo	Neuraltus Pharmaceuticals, Inc.	NULL	Completed	21 Years	75 Years	Both	56	Phase 1	United States